US FDA Looks To Standardize Premarketing Safety Assessments
US FDA Looks To Standardize Premarketing Safety Assessments
$131.00
A US Food and Drug Administration initiative to standardize safety assessments of new drug and biologic applications could mean changes in how sponsors classify clinical trial adverse events and the types of information companies routinely submit to the agency.
Author: Informa Pharma Intelligence
Publisher: Pinksheet
- Description
Pink Sheet spoke with Ellis Unger of the Premarket Safety Assessment Working Group at the United States Food and Drug Administration who says the group is overseeing projects aimed at bringing more standardization to NDA and BLA safety assessments across application and review divisions. Standardizations that could bring changes to how sponsors classify clinical trial adverse events and the types of information companies routinely are asked to submit to the agency. Unger says the initiative started in January 2017 and is part of the Center for Drug Evaluation and Research’s broader effort to modernize the new drug review process.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Roche: We’ve Abandoned Budgets And It’s Liberated Employees 
Sign up to the